Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.7%

6 terminated/withdrawn out of 29 trials

Success Rate

79.3%

-7.2% vs industry average

Late-Stage Pipeline

10%

3 trials in Phase 3/4

Results Transparency

43%

10 of 23 completed trials have results

Key Signals

10 with results

Enrollment Performance

Analytics

Phase 1
16(55.2%)
Phase 2
10(34.5%)
Phase 3
3(10.3%)
29Total
Phase 1(16)
Phase 2(10)
Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (29)

Showing 20 of 29 trials
NCT06257758Phase 1Terminated

A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors

Role: lead

NCT05700669Phase 1Completed

Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors

Role: lead

NCT03579628Phase 1Completed

AsiDNA (a DNA Repair Inhibitor) Administered IntraVenously in Advanced Solid Tumors

Role: lead

NCT00865969Phase 2Completed

Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma

Role: collaborator

NCT01655693Phase 3Completed

Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma

Role: lead

NCT01188707Phase 1Terminated

A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer

Role: collaborator

NCT01310244Phase 1Completed

MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC

Role: collaborator

NCT01385748Phase 2Completed

Efficacy and Safety Study of Clonidine Lauriad® to Treat Oral Mucositis

Role: lead

NCT02548806Phase 1Completed

Phase 1 PK, Bioavailability, Safety Study of Clonidine MBT w Catapres in Healthy Volunteers

Role: lead

NCT00548704Phase 2Completed

A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracyclines

Role: lead

NCT00548561Phase 2Completed

Efficacy of TopotectTM (Dexrazoxane) for Accidental Extravasation of Anthracyclines

Role: lead

NCT00432107Phase 2Completed

A Study to Assess APO866 for the Treatment of Advanced Melanoma

Role: lead

NCT00435084Phase 1Completed

A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL

Role: lead

NCT01317927Phase 1Completed

A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies

Role: collaborator

NCT00437736Phase 1Completed

A Phase I Dose Finding Study of APO010 in Patients With Solid Tumors

Role: lead

NCT01045915Phase 1Terminated

Safety and Efficacy Study of Electrotransfer of Plasmid AMEP to Treat Advanced or Metastatic Melanoma

Role: lead

NCT01764009Phase 1Withdrawn

Safety and Efficacy of Intramuscular Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma

Role: lead

NCT00878722Phase 1Completed

Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy

Role: lead

NCT00274651Phase 2Terminated

A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas

Role: lead

NCT00873119Phase 2Completed

Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary

Role: lead